学名药的全球市场:现状分析与预测(2021年～2027年)

全球学名药的市场规模在预测期间(2021年～2027年)中预计将以约7％的年复合成长率成长。

学名药市场的增长可能受到全球疾病流行、新兴经济体强大的饮料基础设施以及药品意识提高的推动。在预测期内，增加中年人口和推出学名药 IV 产品也有望推动市场增长。

本报告提供全球学名药市场的相关调查，提供市场洞察，市场趋势，竞争模式，企业概要等全面性资讯。

目录

第1章 市场简介

• 市场定义
• 限制
• 相关利益者
• 报告所使用的货币

第2章 调查方法或假设

• 学名药市场调查流程
• 学名药市场调查手法
• 预测方法
• 受访者简介
• 学名药市场调查的主要目的

第3章 市场摘要

第4章 摘要整理

第5章 学名药市场上COVID-19影响

第6章 学名药市场收益(2019年～2027年)

第7章 市场洞察:各类型

• 简便非专利
• 超级非专利药品
• 生物相似药

第8章 市场洞察:各应用领域

• 神经疾病
• 心臟病
• 代谢性疾病
• 感染疾病
• 整形外科疾病
• 泌尿生殖系统/荷尔蒙性疾病
• 呼吸疾病
• 其他

第9章 市场洞察:各流通管道

• 离线
• 线上

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他的欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 其他的亚太地区
• 其他

第11章 学名药市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 学名药市场机会

第13章 学名药市场趋势

第14章 相关法规

第15章 需求与供给面的分析

• 需求面分析
• 供给面分析

第16章 价值链分析

第17章 竞争模式

• 竞争情形
  • 波特的五力分析

第18章 公司概要

• Cipla Ltd.
• Pfizer Inc.
• Fresenius Medical Care AG & Co. KGaA
• Aurobindo Pharma Limited
• Amneal Pharmaceuticals Inc.
• Alkem Laboratories Limited
• Teva Pharmaceutical Industries Limited
• Mylan N.V.
• Lupin Limited
• Sanofi S.A.

第19章 免责声明

The Generic Drugs market is predicted to grow at a CAGR of ~7% between 2021 and 2027. Key factors influencing the growth of the generic drugs market are the increasing prevalence of diseases around the world, strong healthcare infrastructure in developed economies, and increased awareness about different available medications around the world. The increasing prevalence of chronic and infectious diseases and the growing geriatric population in most countries coupled with rising intravenous generic product launches are further expected to drive the growth of the market during the forecast period. For instance, in July 2021, Generic Ferumoxytol, an injectable drug used to treat iron deficiency anemia (IDA), was launched in the U.S. by Sandoz. The rise in product launches of injectable generic products in developed countries is further expected to drive market growth. In addition, according to the National Health Interview Survey (NHIS) ~51.8 % of adults have a minimum of one chronic disease and 27.2 % of adults have several chronic diseases. Furthermore, according to the World Health Organization (WHO), the demand for generic medicines increased because of the prevalence of chronic diseases, propelling the generic drugs industry to new heights.

Some of the major players operating in the market include: Cipla Ltd., Pfizer Inc., Fresenius Medical Care AG & Co. KGaA, Aurobindo Pharma Limited, Amneal Pharmaceuticals Inc., Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Mylan N.V., Lupin Limited, and Sanofi S.A.

Insights Presented in the Report

"Amongst Type, biosimilar category to witness higher incremental gain during the forecast period"

Based on type, the generic drugs market is segmented into simple generic, super generic, biosimilar, and others in 2020, biosimilar drugs had a dominating share in the market. This is mainly due to the presence of a well-established infrastructure for chemical-based drugs and the increasing prevalence of chronic diseases across the world. In addition, the increasing demand for the more targeted and patient-specific drugs along with increasing investment in generic medicines because of low cost and greater opportunities in the developing nations like India and China is further expected to drive the market.

"Amongst Application, cardiovascular diseases category held a significant share in 2020"

Based on application, the market is bifurcated into neurological diseases, cardiological diseases, metabolic diseases, infectious diseases, orthopedic diseases, genitourinary/hormonal diseases, respiratory diseases, and others. Among these, cardiovascular is expected to witness significant growth in the forecast period. This is mainly due to the rising number of patients suffering from CVDs. For instance, in the U.S., about 18 million adults aged 20 and older have coronary artery disease (CAD). Furthermore, according to American Heart Association (AHA), coronary heart diseases cause 1 in every 7 deaths in the U.S., resulting in about 366,800 deaths each year. In addition, in 2020, there were 2.2 million new cases of lung cancer reported.

"Amongst Distribution Channel, online to witness higher incremental gain during the forecast period"

Based on distribution channel, the market is bifurcated into offline and online. The online segment is expected to witness significant CAGR owing to the growing penetration of e-pharmacy platforms across the world coupled with increasing awareness regarding services offered by e-pharmacy. Furthermore, the growing focus on digitization and rising internet penetration in developing nations are some other key factors driving the market.

"APAC is expected to be the Fastest-Growing Region in Global Generic Drugs Market During 2021-2027F"

For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Mexico, Rest of North America); Europe (UK, Germany, France, Italy, Spain, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and Rest of World. In 2020, APAC dominated the market on account of the rising research and development initiatives and the presence of a large number of pharmaceutical companies in countries such as India and China of the region. For instance, as per the India Brand Equity Foundation, India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the U.S., and 25% of all medicine in the U.K.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts

• The report presents a quick review of overall industry performance at one glance

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

• The study comprehensively covers the market across different segments

• Deep dive regional level analysis of the industry

Customization Options:

The Generic Drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Generic Drugs Market
• 2.2. Research Methodology of the Generic Drugs Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Generic Drugs Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GENERIC DRUGS MARKET COVID-19 IMPACT

6 GENERIC DRUGS MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY TYPE

• 7.1. Simple
• 7.2. Super
• 7.3. Biosimilar

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Neurological Diseases
• 8.2. Cardiological Diseases
• 8.3. Metabolic Diseases
• 8.4. Infectious Diseases
• 8.5. Orthopedic Diseases
• 8.6. Genitourinary/Hormonal Diseases
• 8.7. Respiratory Diseases
• 8.8. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Offline
• 9.2. Online

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of America
• 10.2. Europe
  • 10.2.1. U.K.
  • 10.2.2. Germany
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. India
  • 10.3.3. Japan
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of the World

11 GENERIC DRUGS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 GENERIC DRUGS MARKET OPPORTUNITIES

13 GENERIC DRUGS MARKET TRENDS

14 LEGAL & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Cipla Ltd.
• 18.2. Pfizer Inc.
• 18.3. Fresenius Medical Care AG & Co. KGaA
• 18.4. Aurobindo Pharma Limited
• 18.5. Amneal Pharmaceuticals Inc.
• 18.6. Alkem Laboratories Limited
• 18.7. Teva Pharmaceutical Industries Limited
• 18.8. Mylan N.V.
• 18.9. Lupin Limited
• 18.10. Sanofi S.A.

19 DISCLAIMER